Claims for Patent: 11,426,306

Summary for Patent: 11,426,306

Title:	Implants with controlled drug delivery features and methods of using same
Abstract:	Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.
Inventor(s):	Haffner David S., Burns Thomas W., Heitzmann Harold A., Curry Kenneth M.
Assignee:	DOSE MEDICAL CORPORATION
Application Number:	US16277858
Patent Claims:	1. A drug delivery ocular implant comprising:an outer shell having a first end and a second closed end, the first end being at least partially open, the outer shell being shaped to define an interior cavity;at least a first drug positioned within the interior cavity;an elastic membrane permeable or semi-permeable to the at least a first drug, the membrane positioned at the first end of the outer shell and mechanically affixed to the outer shell to form a gasket to close the first end; anda retention protrusion on the second closed end of the outer shell, wherein the retention protrusion is configured to anchor the ocular implant at a target tissue site in an eye.2. The implant of claim 1 , wherein the gasket limits the fluid communication between interior and exterior portions to that occurring through the elastic membrane.3. The implant of claim 1 , wherein the outer shell comprises one or more surface irregularities which extend from the surface of the outer shell to inhibit migration of the implant from an implanted position.4. The implant of claim 3 , wherein the surface irregularity is anchored in position by friction fit to prevent growth of tissue.5. The implant of claim 3 , wherein the one or more surface irregularities comprise one or more of ridge claim 3 , groove claim 3 , relief claim 3 , annular groove claim 3 , ribbing claim 3 , or projections.6. The implant of claim 1 , wherein the implant comprises one or more annular ribs on an exterior surface of the implant.7. The implant of claim 6 , wherein the plurality of annular ribs are spaced longitudinally along the implant between the proximal end and the distal end.8. The implant of claim 1 , wherein the retention protrusion is barb-like or spike-like.9. The implant of claim 1 , wherein the first drug is selected from a prostaglandin claim 1 , a prostaglandin analog claim 1 , and a prostaglandin inhibitor.10. The implant of claim 9 , wherein the first drug is travoprost.11. A drug delivery ocular implant comprising:an outer shell shaped to define an interior space, the outer shell having a sidewall, one closed distal end, and one proximal end, the proximal end being at least partially open;at least a first drug contained within the interior space;a membrane mechanically affixed to and sealing the proximal end, the membrane controlling flow of the drug out of the implant, wherein the membrane has elastic properties; andan anchor on the closed distal end.12. The implant of claim 11 , wherein the outer shell comprises one or more surface irregularities which extend from the surface of the outer shell to inhibit migration of the implant from an implanted position.13. The implant of claim 12 , wherein the one or more surface irregularities comprise one or more of ridge claim 12 , groove claim 12 , relief claim 12 , hole claim 12 , annular groove claim 12 , barbs claim 12 , ribbing claim 12 , or projection.14. The implant of claim 11 , wherein the implant comprises one or more annular ribs on an exterior surface of the implant.15. The implant of claim 14 , wherein the plurality of annular ribs are spaced longitudinally along the implant between the proximal end and the distal end.16. The implant of claim 11 , wherein the retention protrusion is barb-like or spike-like.17. The implant of claim 11 , wherein the first drug is selected from a prostaglandin claim 11 , a prostaglandin analog claim 11 , and a prostaglandin inhibitor.18. The implant of claim 17 , wherein the first drug is travoprost.19. The implant of claim 11 , wherein the membrane is permeable or semi-permeable to the first drug.